ITI Pharma and Healthcare Fund Direct Growth

ITI Pharma and Healthcare Fund Direct Growth

+24.46%
3Y annualised
+0.33% 1D
1M
6M
1Y
3Y
All
NAV: 21 May '26
₹18.49
Min. for SIP
₹500
Fund size (AUM)
₹229.56 Cr
Expense ratio
2.50%
Rating
2

Return calculator

Monthly investment
₹5,000
Over the pastTotal investmentWould've becomeHistoric returnsReturns
3 months₹15,000₹15,835
+5.57%
6 months₹30,000₹32,208
+7.36%
1 year₹60,000₹63,713
+6.19%
3 years₹1,80,000₹2,19,201
+21.78%

Holdings (39)

NameSectorInstrumentsAssets
Sun Pharmaceutical Industries Ltd.HealthcareEquity12.40%
Divi's Laboratories Ltd.HealthcareEquity8.83%
Apollo Hospitals Enterprise Ltd.HealthcareEquity6.25%
Max Healthcare Institute Ltd.HealthcareEquity5.22%
Torrent Pharmaceuticals Ltd.HealthcareEquity4.82%
Lupin Ltd.HealthcareEquity4.44%
Aurobindo Pharma Ltd.HealthcareEquity4.36%
Laurus Labs Ltd.HealthcareEquity4.24%
Fortis Healthcare Ltd.HealthcareEquity3.11%
Cohance Lifesciences Ltd.HealthcareEquity3.08%
Neuland Laboratories Ltd.HealthcareEquity3.05%
Alkem Laboratories Ltd.HealthcareEquity2.93%
Glenmark Pharmaceuticals Ltd.HealthcareEquity2.69%
Aster DM Healthcare Ltd.HealthcareEquity2.24%
Mankind Pharma Ltd.HealthcareEquity1.91%
Sai Life Sciences Ltd.HealthcareEquity1.84%
Dr. Reddy's Laboratories Ltd.HealthcareEquity1.82%
Abbott India Ltd.HealthcareEquity1.79%
Park Medi World Ltd.HealthcareEquity1.67%
Cipla Ltd.HealthcareEquity1.64%
Ipca Laboratories Ltd.HealthcareEquity1.50%
Linde India Ltd.ChemicalsEquity1.37%
Sun Pharmaceutical Industries Ltd.HealthcareFutures1.36%
Shaily Engineering Plastics Ltd.ChemicalsEquity1.29%
Jubilant Ingrevia Ltd.ChemicalsEquity1.28%
SBI Life Insurance Company Ltd.InsuranceEquity1.26%
FDC Ltd.HealthcareEquity1.21%
Piramal Pharma Ltd.HealthcareEquity1.20%
Biocon Ltd.HealthcareEquity1.19%
Healthcare Global Enterprises Ltd.HealthcareEquity1.09%
Rainbow Children's Medicare Ltd.HealthcareEquity0.99%
Glaxosmithkline Pharmaceuticals Ltd.HealthcareEquity0.94%
Standard Engineering Technology LimitedCapital GoodsEquity0.91%
Shilpa Medicare Ltd.HealthcareEquity0.88%
Poly Medicure Ltd.HealthcareEquity0.79%
Caplin Point Laboratories Ltd.HealthcareEquity0.78%
Supriya Lifescience Ltd.HealthcareEquity0.77%
Zydus Lifesciences Ltd.HealthcareEquity0.65%
Syngene International Ltd.HealthcareEquity0.45%
See All

Minimum investments

Min. for 1st investment
₹5,000
Min. for 2nd investment
₹1,000
Min. for SIP
₹500

Returns and rankings

Annualised returns
Absolute returns
Name6M1Y3YAll
Fund returns+6.0%+7.3%+24.5%+14.5%
Category average (Equity Sectoral)+0.2%-2.1%+22.1%--
Rank (Equity Sectoral)--189--

Exit load, stamp duty and tax

Exit load

Exit load of 0.50%, if redeemed within 3 months.

Stamp duty on investment: 0.005% (from July 1st, 2020)

from July 1st 2020

Tax implication

If you redeem within one year, returns are taxed at 20%. If you redeem after one year, returns exceeding Rs 1.25 lakh in a financial year are taxed at 12.5%.
Check past data

Fund management

RB
Rajesh Bhatia
Jun 2024 - Present
View details

Education
Mr. Bhatia has done B.Com, ACMA and CFA
Experience
Prior to joining ITI Mutual Fund, he was associated with The Investment Trust Of India Ltd, Simto Investment Company Ltd, ProAlpha Systematic Capital, Heritage India Advisors Ltd and Reliance Capital Asset Management Ltd

AS
Animesh Singh
May 2026 - Present
View details

Education
Post Graduate Diploma in Management, Bachelor of Honours -(Economics) CFA - USA Certification.
Experience
Prior to joining the ITI AMC, he was associated with Julius Baer wealth Advisor, Centrum Wealth, Nippon Life India Asset Management Ltd, Reliance Portfolio Management Services, KSBL and SSKI Securities.

ND
Nilay Dalal
May 2026 - Present
View details

Education
Mr. Nilay holds a degree in B.E (Computer) from D.J Sanghvi College of Engg & master’s in management studies in KJ Somaiya Institute of Management Studies & Research.
Experience
Prior to joining ITI Mutual Fund, he has with Axis Asset Management Company, SBI Life Insurance Company Ltd & MAQ Software Pvt Ltd.

About ITI Pharma and Healthcare Fund Direct Growth

ITI Pharma and Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by ITI Mutual Fund. This scheme was made available to investors on 14 May 2018. Rajesh Bhatia is the Current Fund Manager of ITI Pharma and Healthcare Fund Direct Growth fund. The fund currently has an Asset Under Management(AUM) of ₹11,161 Cr and the Latest NAV as of 21 May 2026 is ₹18.49. The ITI Pharma and Healthcare Fund Direct Growth is rated Very High risk. Minimum SIP Investment is set to ₹500. Minimum Lumpsum Investment is ₹5,000. Exit load of 0.50%, if redeemed within 3 months. ;

Investment Objective

The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare.
Fund benchmarkNIFTY Healthcare Total Return Index.

Fund house

Rank (total assets)--
Total AUM₹11,161.50 Cr
Date of Incorporation14 May 2018
Phone022-66214999
Launch Date14 May 2018
AddressITI Asset Mangement Limited,ITI House, Building no. 36,Dr. R. K. Shirodkar Marg, Parel, Mumbai 400012
CustodianDeutsche Bank
Registrar & Transfer AgentKFin Tech
AddressKarvy House, No. 46, 8-2-609/K, Avenue 4, Street No.1 Banjara Hills,